A Phase 3 interventional study of Icatibant and Placebo in Angioedema, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 4th largest by enrollment, is the only one that started in 2004, is one of 7 in phase 3, and was the 1st registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →
icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2004.
This study's enrollment of 84 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 26 across the 10 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
58 studies in Angioedemas, Hereditary by Takeda: 3 open now, 4 under way, none of them phase 3. Of 52 finished, 33 (63%) have results posted.
Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 12th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2004, is one of 23 in phase 3, and was the 1st registered.
Takeda’s Angioedemas, Hereditary studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 58 in Angioedemas, Hereditary:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of Icatibant, a bradykinin antagonist in the treatment of acute cutaneous and/or abdominal attacks in patients with hereditary angioedema (HAE).
This Phase II/III study consisted of two parts: A controlled phase and An Open label extension(OLE) phase. The controlled phase describes the double blind part of the study and was intended to evaluate the efficacy of icatibant in decreasing the time to onset of symptom relief compared with placebo for the first treated cutaneous and/or abdominal attack in randomised patients. Patients experienced a laryngeal attack were not randomised, but treated with open label icatibant according to the controlled phase procedures and assessments. The outcome of this group was to be reported descriptively. After treatment of the first attack in the controlled phase, the patients were eligible to enter the OLE phase. In the OLE phase, patients who experienced angioedema attacks severe enough to warrant treatment were to be treated with s.c. icatibant as appropriate until the end of the study.The OLE phase became a modified open label extension where all 56 patients who had been randomised and the last randomised patient had concluded the double-blind phase. The modified open label extension period permitted treatment for patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the double blind phase was still ongoing.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
This study's enrollment of 84 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Browse Angioedemas, Hereditary studies →Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
First submitted before Shire became part of Takeda.
Compared within Angioedemas, Hereditary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Angioedema. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who were randomized to icatibant in the controlled phase after they had an eligible first in-study attack.
Drug: Icatibant
Patients who were randomized to placebo in the controlled phase after they had an eligible first in-study attack.
Drug: Placebo
Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
Drug: Icatibant
Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing (they were not treated during the Controlled phase but treated with icatibant during the Open Label Extension Phase (OLE) )
Drug: Icatibant
30 mg (3mL) subcutaneous icatibant injection in the abdominal region
Also known as: Brand name, Firazyr®
Solution for injection, matched to study drug Single dose: 3 mL
Time to Onset of Symptom Relief (TOSR)
The primary efficacy endpoint was TOSR assessed by the patient using a Visual Analogue Scale (VAS). The VAS is a scale used to measure intensity of each symptom of the attack at baseline and at the pre-determined time points throughout treatment period. It consists of a horizontal 10cm line, with the 0 point corresponding to a state where patient experiences no symptoms at all and the 10cm point represents the worst symptoms ever experienced by patient. The patient indicates his/her current state of symptoms by drawing a mark across the horizontal line. TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the 3 primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain. The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe.
Time frame: 5 days
Time to Regression (Start of Improvement) According to Patient
This parameter assessed the time to regression (start of improvement) of observable(visible) symptoms according to the patients. Patients were asked "Report date and time when you feel that your symptoms start to improve".
Time frame: 5 days
Time to Almost Complete Symptom Relief
The time to almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least 3 consecutive measurements for all symptom.
Time frame: 5 days
| Milestone | Randomized -Icatibant | Randomized -Placebo | Controlled Open-label / Laryngeal Attack | Untreated Patients at the Baseline |
|---|---|---|---|---|
| Started | 27 | 29 | 8 | 20 |
| Completed | 23 | 26 | 3 | 0 |
| Not completed | 4 | 3 | 5 | 20 |
| Milestone | Randomized -Icatibant | Randomized -Placebo | Controlled Open-label / Laryngeal Attack | Untreated Patients at the Baseline |
|---|---|---|---|---|
| Started | 23 | 26 | 3 | 20 |
| Completed | 10 | 11 | 1 | 15 |
| Not completed | 13 | 15 | 2 | 5 |
The primary efficacy endpoint was TOSR assessed by the patient using a Visual Analogue Scale (VAS). The VAS is a scale used to measure intensity of each symptom of the attack at baseline and at the pre-determined time points throughout treatment period. It consists of a horizontal 10cm line, with the 0 point corresponding to a state where patient experiences no symptoms at all and the 10cm point represents the worst symptoms ever experienced by patient. The patient indicates his/her current state of symptoms by drawing a mark across the horizontal line. TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the 3 primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain. The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe.
| Hours | Randomized -Icatibant | Randomized -Placebo |
|---|---|---|
| Time to Onset of Symptom Relief (TOSR) | 2.5 (1.1 to 6.0) | 4.6 (1.8 to 10.2) |
This parameter assessed the time to regression (start of improvement) of observable(visible) symptoms according to the patients. Patients were asked "Report date and time when you feel that your symptoms start to improve".
| Hours | Randomized -Icatibant | Randomized -Placebo |
|---|---|---|
| Time to Regression (Start of Improvement) According to Patient | 0.8 (0.5 to 2.0) | 16.9 (3.2 to NA) |
The time to almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least 3 consecutive measurements for all symptom.
| Hours | Randomized Control Trial-icatibant | Randomized Control Trial-placebo |
|---|---|---|
| Time to Almost Complete Symptom Relief | 8.5 (2.5 to 31.5) | 19.4 (10.2 to 55.7) |
Collected over An AE was assigned to the controlled phase if the event start date was between the first treatment of the first attack and the first treatment in the OLE phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Controlled Phase- Icatibant (Randomized Subjects ) | — | 0/27 (0%) | 12/27 (44.4%) |
| Controlled Phase- Placebo (Randomized Subjects | — | 0/29 (0%) | 19/29 (65.5%) |
| Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack) | — | 1/8 (12.5%) | 6/8 (75%) |
| Open Label Extension Phase- Icatibant (Previously Randomized) | — | 3/49 (6.1%) | 39/49 (79.6%) |
| Open Label Extension -Icatibant (Subjects w/ Laryngeal Attack) | — | 0/3 (0%) | 3/3 (100%) |
| Open Label Extension Phase(Untreated Patients at the Baseline) | — | 0/20 (0%) | 17/20 (85%) |
| Event | Controlled Phase- Icatibant (Randomized Subjects ) | Controlled Phase- Placebo (Randomized Subjects | Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack) | Open Label Extension Phase- Icatibant (Previously Randomized) | Open Label Extension -Icatibant (Subjects w/ Laryngeal Attack) | Open Label Extension Phase(Untreated Patients at the Baseline) |
|---|---|---|---|---|---|---|
| HAE attackCongenital, familial and genetic disorders | 0/27 | 0/29 | 1/8 | 1/49 | 0/3 | 0/20 |
| PancreatitisGastrointestinal disorders | 0/27 | 0/29 | 0/8 | 1/49 | 0/3 | 0/20 |
| Chest PainGeneral disorders | 0/27 | 0/29 | 0/8 | 1/49 | 0/3 | 0/20 |
| Event | Controlled Phase- Icatibant (Randomized Subjects ) | Controlled Phase- Placebo (Randomized Subjects | Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack) | Open Label Extension Phase- Icatibant (Previously Randomized) | Open Label Extension -Icatibant (Subjects w/ Laryngeal Attack) | Open Label Extension Phase(Untreated Patients at the Baseline) |
|---|---|---|---|---|---|---|
| Headache/MigraineNervous system disorders | 0/27 | 2/29 | 2/8 | 0/49 | 2/3 | 1/20 |
| Hereditary angioedemaCongenital, familial and genetic disorders | 4/27 | 5/29 | 4/8 | 17/49 | 1/3 | 5/20 |
| InfectionsInfections and infestations | 4/27 | 4/29 | 1/8 | 20/49 | 0/3 | 7/20 |
| DizzinessInvestigations | 2/27 | 1/29 | 0/8 | 0/49 | 1/3 | 0/20 |
| Administration site conditionsGeneral disorders | 3/27 | 4/29 | 0/8 | 11/49 | 1/3 | 3/20 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 1/27 | 0/29 | 0/8 | 1/49 | 1/3 | 2/20 |
| NauseaGastrointestinal disorders | 0/27 | 3/29 | 0/8 | 2/49 | 0/3 | 0/20 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 2/27 | 0/29 | 0/8 | 0/49 | 0/3 | 0/20 |
| PruritusSkin and subcutaneous tissue disorders | 0/27 | 2/29 | 0/8 | 0/49 | 0/3 | 0/20 |
| ContusionInjury, poisoning and procedural complications | 0/27 | 0/29 | 0/8 | 3/49 | 0/3 | 0/20 |
| Age, Continuous(Years) | Randomized -Icatibant | Randomized -Placebo | Controlled Open-label / Laryngeal Attack | Untreated Patients at the Baseline | Total |
|---|---|---|---|---|---|
| Mean | 34.8 ± 9.81 | 34.9 ± 11.37 | 47.1 ± 13.86 | 37.4 ± 11.48 | 36.6 ± 11.5 |
| Sex: Female, Male(Participants) | Randomized -Icatibant | Randomized -Placebo | Controlled Open-label / Laryngeal Attack | Untreated Patients at the Baseline | Total |
|---|---|---|---|---|---|
| Female | 16 | 21 | 5 | 15 | 57 |
| Male | 11 | 8 | 3 | 5 | 27 |
Ran from Dec 2004 to primary completion in Jul 2006, 18 months.
Results were first posted in Dec 2013, 7 years 5 months after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 18 months is below that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Icatibant